Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis

Abstract

Aim

Discordant efficacy and safety of conventional transarterial chemoemblolization (cTACE) versus drug-eluting beads (DEB)-TACE were reported by previous trials. Our meta-analysis was to update and re-evaluate the efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma (HCC).

Methods

Literatures were searched in Pubmed, Medline and Embase to screen citations from January 1990 to March 2015 in this study. Studies of parallel group design comparing cTACE and DEB-TACE for HCC were screened. After independent review of 2603 citations by two authors, nine studies were identified as meeting the inclusion criteria.

Results

Our study showed that DEB-TACE increased the tumor complete response rate (OR = 1.38, 95% CI: 1.01 to 1.89), overall survival rate (OR = 1.41, 95% CI: 1.01 to 1.98) and survival time (WMD = 3.03, 95% CI: 0.79 to 5.27) with less common adverse events (OR = 0.59, 95% CI: 0.41 to 0.84). However, DEB-TACE has similar partial response rate (OR = 1.00, 95% CI: 0.67 to 1.49), objective response rate (OR = 1.21, 95% CI: 0.94 to 1.56), disease control rate (OR = 1.14, 95% CI: 0.81to 1.58) and serious adverse events (OR = 0.86, 95% CI: 0.50 to 1.49), compared to cTACE, respectively.

Conclusions

Our study indicated that DEB-TACE has higher tumor complete response rate and better survival rate in patients with HCC compared to cTACE, which should be interpreted with caution. Furthermore, DEB-TACE has a better safety than cTACE with less common adverse events.

from #Esophageal Cancer via a.lsfakia on Inoreader http://ift.tt/29xqsQ6
via IFTTT